Weight Trajectories Over 48 Weeks of Treatment With a Digital Health Application in Adults With Obesity Across 4 Consecutive Prescription Periods: Retrospective Real-World Cohort Study (Preprint)
BACKGROUND Digital health applications (Digitale Gesundheitsanwendungen, DiGA) are reimbursed medical devices in German statutory health care and are prescribed for obesity in renewable 12-week periods. Randomized trials have shown the efficacy of one such app, Oviva Direkt für Adipositas, at 12 weeks and 6 months, but whether weight loss persists over a full year of repeated prescriptions in routine care is unknown. OBJECTIVE This study aimed to describe body weight over 4 consecutive 12-week prescription periods (48 weeks of treatment) of a DiGA for obesity in routine care. METHODS In this retrospective, single-arm cohort study of routinely collected app data, adults with a baseline body mass index (BMI) of at least 30 kg/m² whose first prescription was verified between August 12 and September 21, 2025, were included. Body weight was self-reported in the app. The primary endpoint was the mean percent change in body weight from baseline to week 48 of treatment (ie, completion of the fourth prescription period) in patients with a valid weight at both time points. Secondary endpoints included the trajectory across periods, the proportions losing at least 3%, 5%, and 10% of baseline weight, the proportion with a BMI below 30 kg/m² at week 48, and covariate-adjusted models with multiple imputation as a sensitivity analysis. RESULTS Of 7569 patients with a valid baseline weight, 386 (5.1%) completed 4 consecutive prescription periods, and 172 of these had a valid weight at week 48. In the completer set (N=172; 146/172, 84.9% female; mean age 57.2, SD 11.0 years), mean body weight decreased from 100.5 (SD 14.9) kg to 92.0 (SD 14.4) kg. The mean percent change at week 48 was −8.28% (95% CI −9.21 to −7.35; t171=−17.50; P<.001; Cohen d=−1.33). Weight loss was largest in the first period (−5.26% at week 12) and slowed thereafter (−7.17% at week 24; −7.84% at week 36). At week 48, 140 of 172 (81.4%) patients had lost at least 3% of baseline weight, 116 (67.4%) at least 5%, and 57 (33.1%) at least 10%; 52 (30.2%) had a BMI below 30 kg/m². No baseline characteristic was significantly associated with weight change at week 48, and the covariate-adjusted mean (−8.35%, 95% CI −9.32 to −7.37) was close to the unadjusted estimate. CONCLUSIONS Patients who completed 4 consecutive prescription periods of a DiGA for obesity and kept reporting their weight lost a mean of 8.3% of baseline weight over 48 weeks, without average regain after the first period. As the analysis is single-arm and restricted to an engaged subgroup, studies of treatment persistence in the broader population are needed.
Authors
- Marco Lehmann (ORCID: https://orcid.org/0000-0002-8817-3365)
- Felix Schirmann (ORCID: https://orcid.org/0000-0002-0057-902X)
- Nathalie Rohmann (ORCID: https://orcid.org/0000-0001-9038-5845)
Publication Details
- Published
- 2026-11-20
- DOI
- https://doi.org/10.2196/preprints.117054
- Primary Topic
- Mobile Health and mHealth Applications
- Type
- preprint